SARS-CoV 2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
The COVID-19 pandemic has claimed the lives of nearly 2 million people worldwide. Following rapid sequencing of SARS-CoV, pharmaceutical companies and academic institutions rapidly generated vaccine candidates on the back of a variety of both established and novel vaccine platforms.
Vaccines accelerated at unprecedented pace to phase development, and in December 2020, two mRNA vaccines and one inactivated vaccine were authorised for use in a number of countries. Additional vaccine platforms and candidates are in late stages of phase 3 testing.